Sign in Subscribe

article

A collection of 632 issues

Circulating Tumor DNA Predicts Recurrence After Liver Metastasis Resection

Skip to content The CRC Digest ◇ RESEARCH Circulating Tumor DNA Predicts Recurrence After Liver Metastasis Resection A systematic review and meta-analysis found that circulating tumor DNA (ctDNA) serves as a biomarker for recurrence after curative resection of colorectal cancer liver metastases, potentially guiding post-surgical surveillance strategies. (Clinical Colorectal Cancer) This

KRAS Mutation Enriches Gut Bacteria Linked to Tumor Growth

Skip to content The CRC Digest ◇ RESEARCH KRAS Mutation Enriches Gut Bacteria Linked to Tumor Growth A study in KRAS-mutant CRC patients and mice found that KRAS reshapes the microbial community, enriching Bacteroides acidifaciens, which predicts poor prognosis and promotes malignant phenotypes in KRAS-mutant tumors. (Cell Host & Microbe) This

Multigene Panel Testing Yield Quantified in Colorectal Cancer Patients

Skip to content The CRC Digest ◇ RESEARCH Multigene Panel Testing Yield Quantified in Colorectal Cancer Patients A systematic review and meta-analysis examined the diagnostic yield of germline multigene panel testing using next-generation sequencing in unselected patients with colorectal cancer, helping clarify how often inherited genetic factors contribute to diagnosis. (Lancet

AI Tool Shows Promise for Scalable Colorectal Cancer Screening

Skip to content The CRC Digest ▪ SCREENING AI Tool Shows Promise for Scalable Colorectal Cancer Screening Researchers describe progress toward practical artificial intelligence applications that could expand access to colorectal cancer screening at scale. (Annals of Oncology) This content is informational only and does not constitute medical advice. Always consult

Developing Quality Programs to Track Colorectal Cancer Screening

Skip to content The CRC Digest Developing Quality Programs to Track Colorectal Cancer Screening A new article proposes features for an ideal tracking system to enhance screening program performance, noting that common issues include suboptimal return rates for stool-based tests, lack of timely colonoscopy after abnormal results, and surveillance recommendations

Calcitriol Modulates Age-Dependent Drug Response in Patient-Derived Colorectal Organoids

Skip to content The CRC Digest Calcitriol Modulates Age-Dependent Drug Response in Patient-Derived Colorectal Organoids Researchers used paired patient-derived normal and tumor colorectal organoids to investigate how calcitriol (the active vitamin D metabolite) modulates chemotherapy response. Dose-response analyses revealed marked interpatient variability, with SN38 being more potent than 5-fluorouracil and

Study Examines Attachment Style, Symptom Distress, and Depression in CRC Survivors

Skip to content The CRC Digest ♥ LIVING WITH CRC Study Examines Attachment Style, Symptom Distress, and Depression in CRC Survivors A cross-sectional study of 90 colorectal cancer survivors who completed treatment within the past three months explored relationships among adult attachment styles, symptom distress, and depressive symptoms, and whether mindfulness

Review Outlines Advances and Challenges to Colonoscopy Quality

Skip to content The CRC Digest ▪ SCREENING Review Outlines Advances and Challenges to Colonoscopy Quality A new article in Gastrointestinal Endoscopy Clinics of North America outlines current advances, challenges, and best practices for high-quality colonoscopy, noting that colorectal cancer remains the third most common cancer by incidence and second most

Age-Stratified Mutation Patterns Reveal Distinct Features in Early-Onset CRC

Skip to content The CRC Digest ◇ RESEARCH Age-Stratified Mutation Patterns Reveal Distinct Features in Early-Onset CRC Analysis of 6,762 samples across four age groups found that early-onset colorectal cancer (diagnosed before age 50) shows different mutation patterns compared to later-onset disease, with implications for testing guidelines and therapeutic development.

Dual Oral Regimen Shows Activity in KRAS G12C–Mutated Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Dual Oral Regimen Shows Activity in KRAS G12C–Mutated Metastatic CRC A phase Ib/II trial evaluated the chemotherapy-free combination of ifebemtinib (a FAK inhibitor) plus garsorasib (a KRAS G12C inhibitor) in previously treated KRAS G12C–mutated metastatic colorectal cancer, showing encouraging antitumor